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initial analysis of the first 18 months of the SPA scheme indicated that the length of 
gefitinib therapy was at least that anticipated by NICE. This study aims to validate 
the length of therapy in a larger cohort with up to 3 years follow-up. Methods: The 
SPA administrative database contained information on packs (30-days therapy/pack) 
dispensed to patients from September 2009 to December 2012. This retrospective 
study included patients registered on the database prior to the end of 2012, fulfill-
ing NICE eligibility criteria and receiving at least 3 packs for which the NHS was 
invoiced. Patients were considered censored if they had ≥ 1 pack recorded in the last 
3 months of the database. Median time to treatment cessation was estimated from 
a Kaplan-Meier curve of packs supplied to patients and the mean number of packs 
dispensed per patients from a parametric failure time model. Results: 883/1160 
registered patients met the study eligibility criteria (460/883 censored). These 883 
patients, for whom the NHS was invoiced the single fixed payment, received a median 
of 13 packs 95%CI[12,14], equivalent to 12.8 months to treatment cessation. A mean of 
19.4 95%CI[18.0, 21.0] packs were dispensed per patient. ConClusions: The results 
of this observational study confirm the average length of gefitinib therapy and mean 
number of packs dispensed in the SPA scheme exceed that assumed by NICE.
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objeCtives: To identify the chemotherapeutic treatment patterns in patients with 
indolent non-hodgkin lymphoma (NHL) treated in the Brazilian Public Healthcare 
System. Methods: A retrospective longitudinal analysis based on the Government 
administrative claims database (Datasus) was performed from January 2008 to 
December 2012. Eligibility criteria were patients with indolent NHL diagnosed until 
January 2012 and starting their first chemotherapy regimen from January 2008 to 
January 2012. This cohort of patients was followed until December 2012, death or loss 
of follow-up. Patients without interruption during treatment and without change in 
medication were considered in the same chemotherapy regimen. Descriptive statis-
tics (average, standard deviation and percentage) of treatment regimens, treatment 
free interval (TFI), age at the beginning of treatment, gender and length of treatment 
were performed. Results: A total of 817 patients with indolent NHL representing 
5,449 APACs (Authorization for High Complexity Procedures) met eligibility criteria. 
The population cohort comprised 50.7% men with an average age of 61.3±14.5years. 
72.2% of the patients had only one chemotherapy regimen, whereas 18.2% had two 
and 9.1% had three or more chemotherapy regimens. Time between diagnose and 
the beginning of treatment was 3.6±6.2 months. The most widely used first chemo-
therapy regimen was cyclophosphamide, vincristine and prednisolone (CVP)(22.2%) 
followed by cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) 
and rituximab(15.7%), cyclophosphamide, vincristine and prednisolone (COP) and 
rituximab(5.6%), chlorambucil and prednisone(4.8%). Average length of treatment 
was 5.0±3.7months. For second chemotherapy scheme, the most widely used regi-
men was CHOP and rituximab(14.1%), CVP(7.5%), interferon(9.3%), chlorambucil 
and prednisone(6.2%). The average length of treatment was 4.0±4.1months, with 
an average TFI of 3.3±4.2months. ConClusions: The most used chemotherapy in 
first regimen was CVP. Rituximab in combinations was present in most patients in 
the first scheme. Rituximab in second scheme in combination with CHOP was the 
most used therapy. The length of treatment was longer in first scheme.
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objeCtives: Within the last decade market authorizations for oral anticancer treat-
ments (OATs) have increased. This analysis aimed at describing the current situ-
ation of OATs and their modalities of use. Methods: An analysis was performed 
from Oncology Analyzer™ (IMS Health, France), a physician survey database covering 
more than 10,000 cancer patients per year treated in both public and private insti-
tutions from multiple French regions. The database includes patient demograph-
ics, diagnosis and treatment patterns. Data was extracted for all types of cancers 
and described as number of patients treated by oral and intravenous (IV) anticancer 
drugs. Data was collected from October 2011 to September 2012. Analyses were split 
into different active anticancer treatment categories and excluded supportive care 
agents. Results: A total of 7426 patients treated with oral and IV anticancer treat-
ments in France were included in the analysis. The male/female ratio was 47%/53% 
and 58% of patients were aged over 60 years old. Patients receiving OATs were mainly 
diagnosed with a solid tumor (74%) such as breast cancer (34%), non-small cell lung 
cancer (8%) and colorectal cancer (7%). OATs represented 45% (54/119) of all molecules 
available (oral and IV) of which 44% (24/54) were cytotoxic chemotherapies, 28% (15/54) 
were targeted therapies, 22% (12/54) were hormonal-therapies and 6% (3/54) were 
immunotherapies. 32% of patients (2,410/7,426) received a regimen containing at least 
one OATs among them 78% received OATs only versus 18% received a combination 
of oral and IV drug. Sixty-one percent of patients aged over 80 years received OATs, 
as compared to 26% of patients aged less than 60 years. ConClusions: The ACTOR 
study is the first analysis focused on the understanding of the pattern of use of OATs. 
One third of cancer patients in France are treated with OATs especially among the 
elderly. Further research is needed to understand the OATs uptake.
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11 SMC; 9 PBAC; 3 TLV; 4 pCODR; 3 INESS. The literature search revealed the follow-
ing WTP-ICERs: NICE (20,000 - 30,000 GBP); SMC (30,000 GBP); PBAC (45,000 – 75,000 
AUD); TLV (777,000 SEK); pCODR and INESS (50,000 – 70,000 CAD). Of the agencies 
with specific EOL policies, the number of drugs recommended as cost-effective 
despite final ICERs greater than the respective WTP-ICERs were 11 (65%) NICE; 5 
(45%) SMC; 0 PBAC and 1 (33%) INESSS. The corresponding figures for the agencies 
with no specific EOL policy were 0 TLV and 4 (100%) pCODR. ConClusions: The 
evidence suggests some HTA bodies treat EOL conditions differently, however the 
example of pCODR suggests this need not depend on having a specific EOL policy. 
In fact, the results for PBAC and INESSS show that having a specific EOL policy is 
no guarantee EOL conditions are treated differently.
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objeCtives: To identify the chemotherapeutic treatment patterns in patients 
with chronic lymphocytic leukemia (CLL) treated in the Brazilian Public Healthcare 
System. Methods: A retrospective longitudinal analysis based on Government 
administrative claims database (Datasus) was performed from January 2008 to 
December 2012. Eligibility criteria were patients with CLL (ICD code C911) diagnosed 
until January 2012 and starting their first chemotherapy regimen from January 2008 
to January 2012. This cohort of patients was followed until December 2012, death or 
loss of follow-up. Patients without interruption during treatment and without change 
in medication were considered in the same chemotherapy regimen. Descriptive sta-
tistics (average, standard deviation and percentage) of treatment regimens, treat-
ment free interval (TFI), age at treatment start, gender and length of treatment were 
performed. Results: A total of 1,538 patients with CLL representing 15,371 APACs 
(Authorization for High Complexity Procedures) met eligibility criteria. The popula-
tion cohort comprised 56.6% men with an average age of 67.4±12.1 years. 55.0% of 
the patients had only one chemotherapy regimen, whereas 44.9% had two and 19.4% 
had three or more chemotherapy regimens. Time between diagnosis and beginning 
of treatment was 4.3±7.6 months. The most widely used first chemotherapy regimen 
was chlorambucil (54.9%), followed by cyclophosphamide, vincristine and predni-
solone (CVP) (9.1%), fludarabine and cyclophosfamide (FC) (8.1%) and chlorambucil 
and prednisone (7.0%). Average length of treatment was 6.3±5.7 months. For second 
chemotherapy scheme, the most widely used regimen was chlorambucil (45.3%), fol-
lowed by FC (11.0%), CVP (7.8%), chlorambucil and prednisone (6.2%) and CHOP (3.5%). 
The average length of treatment was 4.9±3.6 months, with an average TFI of 3.5±5.0 
months. ConClusions: Chlorambucil was the most used therapy as both first and 
second chemotherapy regimen. There was a decreasing of Chlorambucil and an 
increasing of FC in second scheme. The length of treatment was longer in first scheme.
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objeCtives: Within the last decade market authorizations for oral anticancer 
treatments (OATs) have increased but no published data are available on their 
use over time. This analysis aimed at describing the evolution of OATs use in 
France. Methods: A retrospective analysis was performed from Oncology Analyzer™ 
(IMS Health, France), a physician survey database covering more than 10,000 cancer 
patients per year treated in both public and private institutions from multiple French 
regions. The database includes patient demographics, diagnosis and treatment pat-
terns. Data were extracted for all cancers patients treated by oral and intravenous 
(IV) anticancer drugs from October 2004 to September 2012. Analyses included active 
anticancer treatments (chemotherapy, targeted therapy, hormonal-therapy, immu-
notherapy) excluding supportive care agents. Results: The proportion of cancer 
patients receiving OATs increased from 2,241/7,891 (28%) to 2,410/7,426 (32%). Data 
showed an increasing use of OATs over time especially among patients aged over 70 
years (i.e. 40% in 2004 vs. 46% for patients in 2012). The proportion of OATs among all 
anticancer drugs (oral and IV) remains stable over time (45.1% in 2005 (41/91) vs. 45.4% 
in 2012 (54/119). The number of molecules available in oral form was stable except for 
targeted therapies (4 in 2004 vs. 15 in 2012). Data related to some molecules available 
in both forms (oral and IV) such as melphalan, fludarabine, topotecan, confirmed 
the preferential use for the oral route of administration over time. ConClusions: 
The Re-ACTOR study confirms the increasing uptake of OATs in oncology in France. 
The number of patients receiving OATs increases over time especially for targeted 
therapies. This trend draws the attention of the necessity to reinforce measures to 
accompany the development of OATs in terms of safety and health care delivery, 
especially for the elderly who require specific attention to provide them with patient 
support tools and programs.
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objeCtives: The UK National Institute for Health and Clinical Excellence (NICE) 
recommended gefitinib as cost-effective for use first line in locally advanced or 
metastatic, EGFR mutation positive NSCLC, when supplied via the SPA scheme, 
based on the mean duration of treatment observed in the IPASS study (8.8 months). 
The single fixed payment under the scheme is triggered at the order of the third 
30-day pack and covers a patient for their total supply of gefitinib treatment. An 
